|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
CA2833908C
(en)
|
2010-04-23 |
2021-02-09 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
CN105408352B
(zh)
|
2013-04-18 |
2020-01-14 |
泰莱托恩基金会 |
通过双重aav载体有效递送大基因
|
|
WO2014194132A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
AU2014324717B2
(en)
|
2013-09-26 |
2020-10-08 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial AAV capsid library for targeted gene therapy
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
IL248102B
(en)
*
|
2014-05-02 |
2022-07-01 |
Genzyme Corp |
aav vectors for gene therapy of the central nervous system and retina
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
EP3209311B1
(en)
|
2014-10-21 |
2024-03-06 |
University of Massachusetts |
Recombinant aav variants and uses thereof
|
|
RU2020109343A
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN112375760A
(zh)
|
2014-11-14 |
2021-02-19 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
EP3224362B1
(en)
*
|
2014-11-26 |
2024-09-25 |
The Regents of The University of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
EP3285780A4
(en)
|
2015-04-24 |
2018-12-19 |
University of Massachusetts |
Modified aav constructions and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
CN114606267A
(zh)
*
|
2015-09-28 |
2022-06-10 |
北卡罗来纳-查佩尔山大学 |
逃避抗体的病毒载体的方法和组合物
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
WO2017070476A2
(en)
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
|
GB201519086D0
(en)
*
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
|
MX2018005084A
(es)
|
2015-11-05 |
2019-05-16 |
Bamboo Therapeutics Inc |
Genes de ataxia de friedreich modificados y vectores para terapia genica.
|
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
ES2869284T3
(es)
*
|
2015-12-11 |
2021-10-25 |
California Inst Of Techn |
Péptidos de diana para dirigir virus adenoasociados (AAV)
|
|
US20180353624A1
(en)
*
|
2015-12-14 |
2018-12-13 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
IL322403A
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Preparations for the treatment of wet age-related macular degeneration
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
IL302748B1
(en)
|
2016-05-18 |
2025-09-01 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
MA44546B1
(fr)
|
2016-06-15 |
2021-03-31 |
Univ California |
Virus adéno-associés variants et procédés d'utilisation
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
|
ES2989940T3
(es)
|
2016-06-29 |
2024-11-28 |
Crispr Therapeutics Ag |
Materiales y métodos para el tratamiento de la ataxia de Friedreich y otros trastornos relacionados
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
|
US11458211B2
(en)
|
2016-07-12 |
2022-10-04 |
The University Of Manchester |
Gene therapy
|
|
MX2019001276A
(es)
|
2016-07-29 |
2019-06-13 |
Univ California |
Viriones de virus adenoasociados con cápside variante y métodos para su uso.
|
|
JP7226801B2
(ja)
*
|
2016-08-16 |
2023-02-21 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
標的遺伝子導入のための方法および組成物
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
EP3526333A4
(en)
*
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
AAV CAPSIDE DESIGNS
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
PT3534922T
(pt)
|
2016-11-04 |
2024-06-07 |
Takeda Pharmaceuticals Co |
Formulações de vírus adenoassociado
|
|
CA3054131C
(en)
|
2017-02-21 |
2021-05-25 |
University Of Florida Research Foundation, Incorporated |
Modified aav capsid proteins and uses thereof
|
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
|
EP3585807A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
EP3585900B1
(en)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
CN110662838B
(zh)
|
2017-02-22 |
2024-05-28 |
克里斯珀医疗股份公司 |
用于基因编辑的组合物和方法
|
|
TW201903146A
(zh)
|
2017-04-14 |
2019-01-16 |
美商銳進科斯生物股份有限公司 |
使用由人類神經或膠細胞產生的重組人類艾杜糖醛酸鹽 (iduronate)-2-硫酸酯酶 (ids) 之黏多醣病ii之治療
|
|
US11752181B2
(en)
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
CN110831611A
(zh)
*
|
2017-05-10 |
2020-02-21 |
马萨诸塞眼科耳科诊所 |
用于修饰病毒的组装活化蛋白(aap)依赖性的方法和组合物
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
US20200121746A1
(en)
*
|
2017-06-30 |
2020-04-23 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
EP3654860A1
(en)
|
2017-07-17 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
CN111448308A
(zh)
|
2017-08-03 |
2020-07-24 |
沃雅戈治疗公司 |
递送aav的组合物和方法
|
|
US20190085358A1
(en)
*
|
2017-08-25 |
2019-03-21 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
CN118006607A
(zh)
|
2017-09-22 |
2024-05-10 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
WO2019067840A1
(en)
|
2017-09-29 |
2019-04-04 |
Voyager Therapeutics, Inc. |
RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
BR112020007405A2
(pt)
*
|
2017-10-18 |
2020-12-08 |
Regenxbio Inc. |
Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
|
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
|
CA3084633A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
|
JP7304878B2
(ja)
*
|
2018-03-16 |
2023-07-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
キャプシド改変による組織特異的遺伝子送達の増加
|
|
CN112218880A
(zh)
*
|
2018-03-29 |
2021-01-12 |
阿斯克肋匹奥生物制药公司 |
逃避中和的肝趋向性重组aav6载体
|
|
EA202092362A1
(ru)
|
2018-04-03 |
2021-01-11 |
Страйдбайо, Инк. |
Вирусные векторы для нацеливания на ткани глаза
|
|
EP3774852A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
CN108660159B
(zh)
*
|
2018-04-12 |
2020-10-30 |
四川大学 |
重组蝙蝠腺相关病毒载体及其用途
|
|
KR102051393B1
(ko)
|
2018-05-04 |
2019-12-04 |
(주)지뉴인텍 |
아데노부속바이러스 기반 유전자 전달용 재조합 벡터 및 이를 이용한 암질환 예방 또는 치료용 조성물
|
|
CA3100066A1
(en)
*
|
2018-05-15 |
2019-11-21 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
US20210230632A1
(en)
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
EP3829718A4
(en)
*
|
2018-07-31 |
2022-06-22 |
Cornell University |
GENE THERAPY PROCEDURES TO CONTROL ORGAN FUNCTION
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
AU2019354995B2
(en)
|
2018-10-02 |
2024-12-12 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
AU2019381776A1
(en)
*
|
2018-11-16 |
2021-07-01 |
AskBio Inc. |
Therapeutic adeno-associated virus for treating Pompe disease
|
|
GB201900702D0
(en)
*
|
2019-01-18 |
2019-03-06 |
Univ Bristol |
Therapy
|
|
WO2020150556A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
KR20210126096A
(ko)
*
|
2019-02-15 |
2021-10-19 |
상가모 테라퓨틱스, 인코포레이티드 |
재조합 aav를 제조하기 위한 조성물 및 방법
|
|
BR112021018776A2
(pt)
|
2019-03-21 |
2021-11-30 |
Stridebio Inc |
Vetores de vírus adenoassociado recombinante
|
|
EP4054254A1
(en)
*
|
2019-03-28 |
2022-09-07 |
Ofinno, LLC |
Core paging handling
|
|
JP7630176B2
(ja)
|
2019-04-01 |
2025-02-17 |
テナヤ セラピューティクス， インコーポレイテッド |
操作されたカプシドを有するアデノ随伴ウイルス
|
|
JP2022530126A
(ja)
*
|
2019-04-23 |
2022-06-27 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
新規アデノ随伴ウイルス（ａａｖ）バリアント及び遺伝子治療のためのその使用
|
|
KR20220004072A
(ko)
|
2019-04-24 |
2022-01-11 |
다카라 바이오 가부시키가이샤 |
뇌에 지향성을 가지는 aav 돌연변이체
|
|
CA3137106A1
(en)
*
|
2019-04-26 |
2020-10-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3990030A1
(en)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
EP3990636A1
(en)
|
2019-06-28 |
2022-05-04 |
CRISPR Therapeutics AG |
Materials and methods for controlling gene editing
|
|
AU2020299026A1
(en)
*
|
2019-07-04 |
2022-01-20 |
Children's Medical Research Institute |
Methods and AAV vectors for in vivo transduction
|
|
US20220265853A1
(en)
*
|
2019-07-12 |
2022-08-25 |
Gene Therapy Research Institution Co., Ltd. |
Adeno-associated virus virion for gene transfer to human liver
|
|
CA3146791A1
(en)
*
|
2019-07-15 |
2021-01-21 |
Meiragtx Uk Ii Limited |
Modified aav capsid proteins for treatment of arthritic disease
|
|
JP7785352B2
(ja)
*
|
2019-08-14 |
2025-12-15 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
遺伝子治療のためのａａｖカプシドバリアント
|
|
CA3151087A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
AU2020363984A1
(en)
*
|
2019-10-10 |
2022-04-28 |
Solid Biosciences Inc. |
Modified aav capsids and uses thereof
|
|
EP4045664A1
(en)
*
|
2019-10-16 |
2022-08-24 |
Wuxi Apptec (Shanghai) Co., Ltd. |
A novel aav variant
|
|
CN114787180A
(zh)
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
MX2022009252A
(es)
*
|
2020-01-29 |
2022-11-09 |
Genzyme Corp |
Proteinas de la capside de virus adeno-asociados modificadas para la terapia genica ocular y metodos de uso de las mismas.
|
|
KR20230020394A
(ko)
|
2020-04-15 |
2023-02-10 |
보이저 테라퓨틱스, 인크. |
Tau 결합 화합물
|
|
PE20230767A1
(es)
|
2020-05-13 |
2023-05-09 |
Voyager Therapeutics Inc |
Redireccion del tropismo de las capsides de aav
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
TW202221125A
(zh)
|
2020-07-27 |
2022-06-01 |
美商航海家醫療公司 |
用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
CN111825772B
(zh)
*
|
2020-07-30 |
2023-10-20 |
中国科学院精密测量科学与技术创新研究院 |
具有变异衣壳蛋白的腺相关病毒及其应用
|
|
TW202214864A
(zh)
|
2020-08-06 |
2022-04-16 |
應用醫學研究基金會 |
用於藉基因療法治療諸如阿茲海默症之Ｔａｕ蛋白病變的病毒顆粒
|
|
PH12023550145A1
(en)
|
2020-08-12 |
2024-03-18 |
UCB Biopharma SRL |
Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
|
|
US12104163B2
(en)
|
2020-08-19 |
2024-10-01 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of Rett syndrome
|
|
AR123369A1
(es)
*
|
2020-08-28 |
2022-11-23 |
Joint Stock Company Biocad |
VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2
|
|
CN113717248B
(zh)
*
|
2020-09-30 |
2022-07-08 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
JP2023545722A
(ja)
*
|
2020-10-07 |
2023-10-31 |
リジェネックスバイオ インコーポレイテッド |
遺伝子治療剤の眼送達のためのアデノ随伴ウイルス
|
|
AU2021358413A1
(en)
|
2020-10-09 |
2023-05-25 |
UCB Biopharma SRL |
Nucleic acid constructs, viral vectors and viral particles
|
|
WO2022093769A1
(en)
*
|
2020-10-28 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
CN116490514A
(zh)
|
2020-10-28 |
2023-07-25 |
北卡罗来纳-查佩尔山大学 |
用于双重聚糖结合aav2.5载体的方法和组合物
|
|
WO2022097008A1
(en)
|
2020-11-03 |
2022-05-12 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
CA3201533A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
AU2021404929A1
(en)
|
2020-12-21 |
2023-07-06 |
Pfizer Inc. |
Methods and systems for improved cell transfection
|
|
JP2024503234A
(ja)
|
2020-12-23 |
2024-01-25 |
ファイザー・インク |
親和性クロマトグラフィーによるａａｖベクターの精製方法
|
|
JP2024505739A
(ja)
|
2021-02-10 |
2024-02-07 |
レジェンクスバイオ インコーポレーテッド |
組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉの治療
|
|
GB202101958D0
(en)
|
2021-02-12 |
2021-03-31 |
Ucl Business Ltd |
Gene therapy for dopamine transporter deficiency syndrome
|
|
CN112961219B
(zh)
*
|
2021-02-24 |
2022-08-12 |
中国农业科学院生物技术研究所 |
重组腺相关病毒、其突变体及其构建方法和应用
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240307553A1
(en)
|
2021-04-01 |
2024-09-19 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
JP2024515902A
(ja)
|
2021-04-26 |
2024-04-10 |
アレクシオン ファーマ インターナショナル オペレーションズ リミテッド |
組織向性が改善されたアデノ随伴ウイルスベクターカプシド
|
|
BR112023023249A2
(pt)
*
|
2021-05-07 |
2024-01-23 |
Oyster Point Pharma Inc |
Fator neurotrófico de codificação de vírion aav e usos do mesmo
|
|
IL308356A
(en)
|
2021-05-12 |
2024-01-01 |
Fond Telethon |
Vector system
|
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
|
AU2022368907A1
(en)
|
2021-10-20 |
2024-05-02 |
University Of Copenhagen |
Rejuvenation treatment of age-related white matter loss
|
|
CA3234666A1
(en)
|
2021-10-28 |
2023-05-04 |
UCB Biopharma SRL |
Nucleic acid constructs, viral vectors and viral particles
|
|
JP2024542015A
(ja)
|
2021-11-02 |
2024-11-13 |
ユニバーシティ オブ ロチェスター |
脳内でのｔｃｆ７ｌ２媒介性髄鞘再生
|
|
IL311861A
(en)
|
2021-11-02 |
2024-06-01 |
Voyager Therapeutics Inc |
Aav capsid variants and uses thereof
|
|
WO2023093905A1
(zh)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
US20250101386A1
(en)
*
|
2021-12-28 |
2025-03-27 |
Chengdu Origen Biotechnology Co., Ltd. |
Modified aav capsid protein and use thereof
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4486890A1
(en)
|
2022-03-01 |
2025-01-08 |
CRISPR Therapeutics AG |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
IL316327A
(en)
|
2022-05-06 |
2024-12-01 |
Novartis Ag |
AAV VP2 fusion polypeptide novel recombinant
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
AR129843A1
(es)
*
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
WO2024015877A2
(en)
*
|
2022-07-12 |
2024-01-18 |
University Of Florida Research Foundation, Incorporated |
Novel aav3b capsid variants with enhanced hepatocyte tropism
|
|
KR20240014846A
(ko)
*
|
2022-07-26 |
2024-02-02 |
숙명여자대학교산학협력단 |
Aav2-anks1a 재조합 바이러스를 포함하는 알츠하이머 질병 치료용 조성물
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
CN116063404B
(zh)
*
|
2022-09-27 |
2025-08-29 |
广州译码基因科技有限公司 |
可提高AAV包装能力的衣壳蛋白MutD及其应用
|
|
GB202216168D0
(en)
|
2022-10-31 |
2022-12-14 |
UCB Biopharma SRL |
Route of administration
|
|
CN116041443B
(zh)
*
|
2022-12-30 |
2023-09-22 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
CN115925819B
(zh)
*
|
2022-12-30 |
2023-10-13 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
CN120769917A
(zh)
*
|
2023-01-05 |
2025-10-10 |
恩沐辑医药有限责任公司 |
嵌合aav及其用途
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4658294A2
(en)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Competitive replacement of glial cells
|
|
WO2024189094A1
(en)
|
2023-03-14 |
2024-09-19 |
UCB Biopharma SRL |
Gene therapy
|
|
GB202304767D0
(en)
*
|
2023-03-30 |
2023-05-17 |
Ucl Business Ltd |
Synthetic AAV Capsid
|
|
WO2024238853A1
(en)
*
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
US20250027087A1
(en)
|
2023-07-21 |
2025-01-23 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
TW202528335A
(zh)
*
|
2023-08-31 |
2025-07-16 |
美商戴諾治療公司 |
衣殼多肽及其使用方法(一)
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
CN118459557B
(zh)
*
|
2024-01-16 |
2024-11-22 |
沈阳兴齐眼药股份有限公司 |
提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025228976A1
(en)
|
2024-04-29 |
2025-11-06 |
UCB Biopharma SRL |
Gene therapy
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|